Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia

Author:

Abrisqueta Pau1,Villamor Neus2,Terol María José3,González-Barca Eva4,González Marcos5,Ferrà Christelle6,Abella Eugenia7,Delgado Julio89,García-Marco Jose A.10,González Yolanda11,Carbonell Felix12,Ferrer Secundino13,Monzó Encarna14,Jarque Isidro15,Muntañola Ana16,Constants Mireia17,Escoda Lourdes18,Calvo Xavier2,Bobillo Sabela1,Montoro José Bruno19,Montserrat Emili9,Bosch Francesc1

Affiliation:

1. Department of Hematology, University Hospital Vall d'Hebron, Universitat Autonoma, Barcelona, Spain;

2. Hematopathology Unit, Hospital Clínic, Barcelona, Spain;

3. Departments of Hematology of Hospital Clínico, Insituto para la Investigación, Hospital Clínico Universitario de Valencia, Valencia, Spain;

4. Institut Català d’Oncologia, Institut de Investigació Biomedica de Bellvitge, Barcelona, Spain;

5. Hospital Clínico Universitario, Salamanca, Spain;

6. Hospital GermansTrias i Pujol, Badalona, Spain;

7. Hospital del Mar, Barcelona, Spain;

8. Hospital de Sant Pau, Barcelona, Spain;

9. Department of Hematology, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain;

10. Hospital Universitario Puerta de Hierro, Madrid, Spain;

11. Hospital Josep Trueta, Girona, Spain;

12. Hospital General Universitario, Valencia, Spain;

13. Hospital Dr Peset, Valencia, Spain;

14. Hospital Arnau de Vilanova, Valencia, Spain;

15. Hospital La Fe, Valencia, Spain;

16. Hospital Mutua de Terrassa, Terrassa, Spain;

17. Althaia, Xarxa Assistencial de Manresa, Manresa, Spain;

18. Hospital Joan XXIII, Tarragona, Spain; and

19. Department of Pharmacy, Hospital Vall d'Hebron, Barcelona, Spain

Abstract

Key Points Maintenance rituximab attained a prolonged PFS and improved the quality of response in patients with detectable disease after R-FCM.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 56 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3